867 on-ppi assessment of reflux-related rejection risk in lung transplant: novel criteria inspired by lyon 2.0
(Source: Gastroenterology)
Source: Gastroenterology - May 6, 2024 Category: Gastroenterology Authors: Wai-Kit Lo, Nirmal Sharma, Hilary J. Goldberg, Walter W. Chan Tags: AGA Abstracts Source Type: research
866 from lyon to lung transplant, take 2.0: pre-transplant reflux severity with adjunctive impedance data predicts chronic rejection and mortality after lung transplant
(Source: Gastroenterology)
Source: Gastroenterology - May 6, 2024 Category: Gastroenterology Authors: Wai-Kit Lo, Nirmal Sharma, Hilary J. Goldberg, Walter W. Chan Tags: AGA Abstracts Source Type: research
Su1637 PREVALENCE OF GASTROPARESIS IN POST-LUNG AND LUNG/HEART TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
(Source: Gastroenterology)
Source: Gastroenterology - May 6, 2024 Category: Gastroenterology Authors: Mukarram Jamat Ali, Wajeeha Aiman, Muhammad Ashar Ali, Alem Mehari, Angesom Kibreab Tags: AGA Abstracts Source Type: research
Tu1212 ABSENT MRS AUGMENTATION ON PRE-TRANSPLANT TESTING IS ASSOCIATED WITH DECREASED BOLUS CLEARANCE AFTER LUNG TRANSPLANT
(Source: Gastroenterology)
Source: Gastroenterology - May 6, 2024 Category: Gastroenterology Authors: Wai-Kit Lo, Nirmal Sharma, Hilary J. Goldberg, Walter W. Chan Tags: AGA Abstracts Source Type: research
Mo1269 PERSONALIZED INTERVENTIONS FOR ESOPHAGEAL DYSMOTILITY PREVENTS EXTRA-ESOPHAGEAL COMPLICATIONS AND IMPROVES SURGICAL OUTCOMES IN LUNG TRANSPLANT RECIPIENTS
(Source: Gastroenterology)
Source: Gastroenterology - May 6, 2024 Category: Gastroenterology Authors: Krissie Lobon, Kathryn Welp, Sara Treat, Ahmed Samy, Dhweeja Dasarathy, Jonathan S. Galati, James C. Slaughter, Shabnam Sarker, Dhyanesh A. Patel, Michael F. Vaezi, Rishi D. Naik Tags: AGA Abstracts Source Type: research
Mo1268 MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE IN LUNG TRANSPLANT RECIPIENTS: ROLE OF SLEEP POSITIONING DEVICE
(Source: Gastroenterology)
Source: Gastroenterology - May 6, 2024 Category: Gastroenterology Authors: Manik Aggarwal, Tyler Greathouse, Marie Budev, Scott L. Gabbard Tags: AGA Abstracts Source Type: research
89 postoperative outcomes of anti-reflux surgery in lung transplant recipients
(Source: Gastroenterology)
Source: Gastroenterology - May 6, 2024 Category: Gastroenterology Authors: William N. Doyle, Monica Stevens, Michael P. Rogers, Rahul Mhaskar, Kapil Patel, Samer Ganam, Christopher DuCoin, Vic Velanovich Tags: SSAT Abstracts Source Type: research
Highlights from the International Society for Heart and Lung Transplantation (ISHLT) 2024
Franz Kafka, arguably the city's most famous citizen, contended that Prague ‘never lets you go’ and in this sense it served as the perfect backdrop to the 44th Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT). From April 10th-13th, 2024, the advanced heart failure, heart transplant and mechanical circulatory support (MCS) communitie s presented the latest basic, translational and clinical science. We hope to present a snapshot of some of this exciting and innovative science and research, focusing on a number of compelling themes across the cardiac-related sessions. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - May 4, 2024 Category: Cardiology Authors: Emer Joyce, Jeff Teuteberg Tags: Perspectives Source Type: research
Umbilical Cord Blood and UC-MSCs Combined with Low-Dose Immunosuppressant in the Treatment of Elderly Patients with Pure Red Cell Aplastic: A Case Series
CONCLUSION: This report provides an effective regimen of using UCB and UC-MSCs combined with low-dose CsA (1-3 mg/kg/d) to treat PRCA, especially for elderly patients with multiple complications who cannot use the conventional dosage.PMID:38698745 | DOI:10.2174/011574888X290378240424075002 (Source: Cell Research)
Source: Cell Research - May 3, 2024 Category: Cytology Authors: Wei-Wei Zhu Sujing Zhuang Zhe Yu Xin Li Tian-Jie Han Yue Ma Li-Jun Li Zhi-Rui Zhao Source Type: research
Umbilical Cord Blood and UC-MSCs Combined with Low-Dose Immunosuppressant in the Treatment of Elderly Patients with Pure Red Cell Aplastic: A Case Series
CONCLUSION: This report provides an effective regimen of using UCB and UC-MSCs combined with low-dose CsA (1-3 mg/kg/d) to treat PRCA, especially for elderly patients with multiple complications who cannot use the conventional dosage.PMID:38698745 | DOI:10.2174/011574888X290378240424075002 (Source: Current Stem Cell Research and Therapy)
Source: Current Stem Cell Research and Therapy - May 3, 2024 Category: Stem Cells Authors: Wei-Wei Zhu Sujing Zhuang Zhe Yu Xin Li Tian-Jie Han Yue Ma Li-Jun Li Zhi-Rui Zhao Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Umbilical Cord Blood and UC-MSCs Combined with Low-Dose Immunosuppressant in the Treatment of Elderly Patients with Pure Red Cell Aplastic: A Case Series
CONCLUSION: This report provides an effective regimen of using UCB and UC-MSCs combined with low-dose CsA (1-3 mg/kg/d) to treat PRCA, especially for elderly patients with multiple complications who cannot use the conventional dosage.PMID:38698745 | DOI:10.2174/011574888X290378240424075002 (Source: Cell Research)
Source: Cell Research - May 3, 2024 Category: Cytology Authors: Wei-Wei Zhu Sujing Zhuang Zhe Yu Xin Li Tian-Jie Han Yue Ma Li-Jun Li Zhi-Rui Zhao Source Type: research
Umbilical Cord Blood and UC-MSCs Combined with Low-Dose Immunosuppressant in the Treatment of Elderly Patients with Pure Red Cell Aplastic: A Case Series
CONCLUSION: This report provides an effective regimen of using UCB and UC-MSCs combined with low-dose CsA (1-3 mg/kg/d) to treat PRCA, especially for elderly patients with multiple complications who cannot use the conventional dosage.PMID:38698745 | DOI:10.2174/011574888X290378240424075002 (Source: Current Stem Cell Research and Therapy)
Source: Current Stem Cell Research and Therapy - May 3, 2024 Category: Stem Cells Authors: Wei-Wei Zhu Sujing Zhuang Zhe Yu Xin Li Tian-Jie Han Yue Ma Li-Jun Li Zhi-Rui Zhao Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
